Everything below concerns quality control. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
=== Counselling and screening === The American College of Obstetricians and Gynecologists recommends all people thinking of becoming pregnant should be offered testing to see if they have thalassemia trait. Genetic counseling and genetic testing are recommended for families who carry a thalassemia trait. Understanding the genetic risk, ideally before a family is started, would hopefully allow families to understand more about the condition and make an informed decision that is best for their family. A number of countries have programs aimed at reducing the incidence of beta-thalassemia:-
== Treatment == There is no cure for Schwartz–Jampel syndrome. Treatment is aimed at reducing muscle stiffness and cramping and may include massage, muscle warming and gradual strengthening exercises. Muscle relaxants or anti-seizure medications, especially carbamazepine, may be used. Eye symptoms such as blepharospasm might be relieved by Botox. Otherwise, a variety of surgical procedures have been found to be effective. Malignant hyperthermia, a potential complication of surgery, is a greater risk for people Schwartz–Jampel syndrome and an important consideration when considering surgery.
SVB was a commercial bank founded in 1983 and headquartered in Santa Clara, California. At its collapse, SVB was the 16th largest bank in the U.S. by total assets and was heavily skewed toward serving companies and individuals from the technology industry. Nearly half of U.S. venture capital-backed healthcare and technology companies were financed by SVB. Companies such as Airbnb, Cisco, Fitbit, Pinterest, and Block, Inc. have been clients of the bank. In addition to financing venture-backed companies, SVB was well known as a source of private banking, personal credit lines, and mortgages to tech entrepreneurs, and specialized lending money to higher-risk new companies. Silicon Valley Bank required an exclusive relationship of those borrowing from the bank. Prior to Thursday March 9, 2023, SVB was in "sound financial condition", according to the California Department of Financial Protection and Innovation, though an increased number of short sellers began to target SVB earlier in the year. Employees received their annual bonuses on March 10, 2023, hours before the government took control of the company. As of the last call report of the bank, filed on December 31, 2022, it held $209 billion in total assets, with $175.5 billion in total deposits, of which the bank estimated $151.6 billion (86.4 percent) were uninsured.
The esophagus has four points of constriction. When a corrosive substance, or a solid object is swallowed, it is most likely to lodge and damage one of these four points. These constrictions arise from particular structures that compress the esophagus. These constrictions are:
Sources: en.wikipedia.org
==== E-I balance as crucial for visual cortex function ==== By computational modeling, Sur’s group proposed that a key feature of visual cortex networks - local and long-range connections between excitatory neurons critically balanced by inhibition - is essential for explaining feature-selective responses. They demonstrated that inhibition and excitation are exquisitely tuned across cortical sites, as demonstrated by imaging and intracellular recordings.
==== Mechanical properties ==== DBHA exhibits shear thinning behaviour and at low strains, storage and loss moduli are independent of strain but past a critical strain, the hydrogel yields and is transformed from a solid to a liquid.
Scottish Labour suspends Wilma Brown, its parliamentary candidate for Cowdenbeath and Kirkcaldy, following reports she liked racist and Islamophobic posts on social media. 11 April – The Department for Science, Innovation and Technology says that the legal fees for Michelle Donelan came to over £19,000. Sally Bunce, the Green Party candidate for Mayor of the Tees Valley in the May election, drops out of the contest saying she does not want to split the vote against the Conservative candidate. Reform UK apologise to the family of their dropped candidate for York Central Tommy Cawkwell for "inactivity" not knowing that he had died. Joe Haines and Lord Donoughue, who were two of Harold Wilson's advisers during his time as prime minister, tell The Times that Wilson had an affair with his deputy press secretary, Janet Hewlett-Davies, during the 1970s. Mid and East Antrim Borough Council is refused permission to rename its town hall complex after the late Queen Elizabeth II. 12 April – Greater Manchester Police launch an investigation into Labour's deputy leader, Angela Rayner, over the sale of her council house amid allegations she broke electoral law by giving false information about her place of residence. Rayner pledges to step down if she is found guilty of any crime. Keir Starmer says that if elected to government, Labour will raise defence spending to 2.5% of GDP. He also makes an "unshakable" commitment to nuclear weapons.
Sources: en.wikipedia.org
== Stress == One important neuropeptide that modulates various aspects of behavior and brain function is UCN III. In the brain, UCN III mRNA was specifically detected in the perifornical region, the medial nucleus of the amygdala, and the median preoptic nucleus. The endocrine, autonomic, and behavioral reactions to stress are all regulated by the corticotropin-releasing factor (CRF) system, which is widely recognized for this function. When stress levels are elevated, UCN III expression increases. UCN III is mostly expressed in areas linked to stress-related behaviours. The origin of projection to the midbrain's median amygdala region is the ventral pre-mammillary nucleus, which exhibited high UCN III positivity. The confirmation of UCN III 's essential role in numerous brain activities linked to anxiety, such as aggression and sexual behaviours, comes from its engagement in this circuit. Mammalian stress reactions are known to be modulated by urocortins. It alters mammals' reactions to stress and functions in the stress recovery mechanism. UCN III and its receptor's function in clinical disorders linked to stress, Stress homeostasis is known to be mediated via a regulatory axis that includes the neuropeptide urocortin III (UCN III ) and the corticotropin-releasing hormone receptor 2 (CRHR2). Cardiovascular disease, sleep apnea, post-traumatic stress disorder, and other stress-related health issues are thought to be associated with dysregulation of this peptide/receptor axis.
=== Kevin: Hair Today, Gone Tomorrow === First aired: 9 December 2010 Meet Kevin, a bully who calls himself a natural. He is a hair-obsessed greaser that makes life miserable for his victims, Anthony and Sam. Mayhem Miller recruits Amateur Wrestler and MMA fighter Tyron Woodley to beat him down. Kevin makes a bet with Mayhem that if he loses all $10,000, he has to cut his hair. In the first round, he tapped out four times and barely escapes with $1,000 with a bruised ego. In the second round, he got TKO'd. Despite technically being allowed to keep his hair, as part of Kevin's apology, he allows Mayhem to cut his hair. Anthony and Sam won $9,000.
In butchery and gastronomy, various tough and inedible meat tissues Cartilage, connective tissue Fascia, connective tissue sheaths Epimysium, fibrous tissue surrounding many muscles Throbbing Gristle, an English avant-garde music and visual arts group Gristle (G.I. Joe), a fictional villain in the G.I. Joe universe Puppy Gristle, a 2002 album by Skinny Puppy The House of Gristle, a 1994 British television series
=== Metabolic === Cachexia can also result from changes in metabolism. Tumors sometimes release molecules that break down fat and muscle, causing cachexia by making it harder for the body to keep up with energy needs. These molecules include lipid mobilizing factor, proteolysis-inducing factor, and mitochondrial uncoupling proteins. In addition, uncontrolled inflammation in people with cachexia increases the body's need for nutrients. The way the body uses nutrients is also changed in cachexia. People with cachexia can have loss of appetite, are less responsive to insulin, and can have increased fat breakdown, all of which make it difficult for the body to properly use food. This is especially true in people with cancer.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.